Meet Our Team
Our experienced management team includes dermatology industry veterans who have held leadership positions in Connetics (acquired by Stiefel, a GSK Company), Peplin (acquired by LEO Pharma A/S), QLT and Gilead. We invite you to get to know them.
Thomas G. Wiggans | Founder & Chief Executive Officer
Tom co-founded Dermira in 2010 and is our Chief Executive Officer and Chairman of our board of directors. He brings over 30 years of experience in specialty pharma and 18 years of experience in dermatology. Prior to founding Dermira, Tom served as Chairman of the board of directors and Chief Executive Officer of Peplin, Inc. until Peplin’s acquisition by LEO Pharma A/S in 2009. Previously, he served as Chairman of the board of directors and Chief Executive Officer of Connetics Corporation until Connetics was acquired by Stiefel Laboratories, Inc. in 2006. Prior to Connetics, he served as President and Chief Operating Officer of CytoTherapeutics Inc., and in various management positions at Ares-Serono S.A., including President of its U.S. pharmaceutical operations and Managing Director of its U.K. pharmaceutical operations. Tom began his career with Eli Lilly and Company.
Tom has served on the boards of various industry organizations, educational institutions and private and public companies, including service on the boards of directors of Onyx Pharmaceuticals, Inc., until its acquisition by Amgen in 2013, Sangamo Biosciences, Inc. and Somaxon Pharmaceuticals, Inc.
In addition, Tom is a member of the board of directors of Biotechnology Innovation Organization, a non-profit educational organization, and is a member of the board of trustees of the University of Kansas Endowment Association. He holds a B.S. in pharmacy from the University of Kansas and an M.B.A. from Southern Methodist University.
Bill Aurora, Pharm.D. | Senior Vice President, Medical Affairs & Compliance
Bill joined Dermira in 2016 as Senior Vice President for Medical Affairs & Compliance. Prior to joining Dermira, Bill was Vice President for Medical Affairs at Neurocrine Biosciences and has held senior scientific and medical affairs roles with Merck Research Laboratories, where he served as Vice President, Global Center for Scientific Affairs, and Amgen, where he served as Vice President, Global Scientific Affairs. Bill also held positions of increasing responsibility with Novartis in the Global Business Development and Licensing group and with Bristol-Myers Squibb in the Medical Affairs group.
Bill earned his Pharm.D. from the University of Texas Health Science Center, San Antonio, and his B.S. in Pharmacy from the University of Texas, Austin. Bill is Board Certified in Psychiatric Pharmacy Practice (BCPP).
Eugene A. Bauer, M.D. | Founder & Chief Medical Officer
Gene is a co-founder of Dermira, our Chief Medical Officer and a member of our board of directors. Prior to founding Dermira, he served as a member of Peplin’s board of directors, and its President and Chief Medical Officer, until its acquisition by LEO Pharma in 2009. He was also the Chief Executive Officer of Neosil Inc., and a co-founder and member of the board of directors at Connetics. Before initiating his career in industry, he served as the Dean of the Stanford University School of Medicine and as Chair of the Department of Dermatology at the Stanford University School of Medicine. He is a Lucy Becker Professor, Emeritus, in the School of Medicine at Stanford University, a position he has held since 2002.
Gene has served on the boards of directors of a number of public and private companies. He is currently a member of the boards of directors of Medgenics, Inc., Dr. Tattoff, Inc., First Wave Technologies, Inc., Cerecor, Inc. and Kadmon Corporation. He previously served as a member of the boards of directors of Protalex, Inc., Vyteris, Inc., Peplin, PetDRx, Inc., Arbor Vita Corp., Patient Safety Technologies, Inc., MediSync Bioservices and Modigene Inc. (renamed PROLOR Biotech, Inc.).
Gene was a U.S. National Institutes of Health, or NIH, funded investigator for 25 years and has served on review groups for the NIH. He has been elected to several societies, including the National Academy of Medicine of the United States. Gene received a B.S. in medicine and an M.D. from Northwestern University.
Angela Boyd | Vice President, Patient Value, Service Innovation & Professional Relations
Angela joined Dermira in January 2015 and serves as Vice President of Patient Value, Service Innovation and Professional Relations. Angela brings nearly 20 years of biotech and pharmaceutical experience with the majority of time focused in the dermatology therapeutic and consumer market. Prior to Dermira, Angela served as Vice President, Medical Relations at SkinCeuticals, a L’Oreal company. She has held various leadership roles in medical relations, sales, marketing and business development at organizations including L’Oreal, Stiefel Laboratories, a GSK company, Connetics, Indevus, Johnson & Johnson, and Alza. She is a member of numerous associations including the American Academy of Dermatology, Women’s Dermatologic Society, American Society for Laser Medicine & Surgery, National Psoriasis Foundation, Acne & Rosacea Society, and the Healthcare Businesswomen’s Association, and has served on the Industry Advisory Council for the American Society for Dermatologic Surgery.
Angela earned a B.S. in Marketing and Business Administration from Limestone College.
Stephen Cheng | Vice President, Information Technology & Facilities
Stephen joined Dermira in 2014 as our Vice President, Information Technology (IT) & Facilities and brings over 20 years of IT management experience in the Life Sciences industry. Prior to Dermira, Stephen served as the Senior Director of IT at Gilead Sciences, Inc., where he was responsible for selecting, deploying and managing all core business applications worldwide. He has also held IT leadership roles across the IT function at other companies, including Connetics, Johnson & Johnson, Ernst & Young LLP and Syntex, Inc.
Stephen earned a B.B.A. in Information Systems from the University of Houston and an M.B.A. from the College of Notre Dame.
Christine Conroy | Senior Vice President, Regulatory Affairs
Christine joined Dermira as our Senior Vice President, Regulatory Affairs in 2014, bringing 25 years of pharmaceutical industry experience to the team, 18 of which are in regulatory. Prior to Dermira, she held senior level regulatory positions at both large pharma and small biotech companies. Most recently, she held positions of increasing responsibility in regulatory affairs and quality assurance at Affymax, Inc., including Senior Vice President, Regulatory Affairs and Quality Assurance after beginning her tenure as Senior Director, Regulatory Affairs. Before joining Affymax, Christine held various senior level positions in the regulatory departments of Genitope Corporation and Roche Global Development. She started her career in the pharmaceutical industry at Syntex in the Medical Services Department.
Christine earned her Pharm.D. from the University of Kansas, School of Pharmacy, and her B.S. in Pharmacy, with Honors, from the University of Colorado, School of Pharmacy.
Janice Drew, MPH | Senior Vice President, Clinical & Project Management
Janice joined Dermira in May 2012 and brings 20 years of industry experience in global clinical development, clinical operations and project management. Before joining Dermira, Janice held leadership positions at Peplin, Allergan, Roche Global Development and Syntex. She has led multidisciplinary global project teams and directly contributed to successful NDAs and MAAs. Her therapeutic experience includes dermatology, urology, cardiovascular, neurology and infectious disease.
Janice has a Master’s degree in Public Health with an emphasis in Health Promotion from California State University, Fullerton, and a Bachelor of Science from the University of California, Irvine.
Jeron Evans | Vice President, Commercial Operations
Jeron joined Dermira in 2016 and serves as Vice President, Commercial Operations. Jeron brings more than 26 years of sales and marketing experience at leading biotech, medical device and pharmaceutical companies. Prior to joining Dermira, Jeron served as a consultant to Dermira and, prior to this role, served as Vice President, Sales at Dendreon Corporation where he oversaw the sales, account management and clinical nursing field teams. Jeron has also served in senior level roles within the commercial organizations at Intuitive Surgical, Abbott, Stiefel Laboratories and Amgen.
Jeron holds an M.B.A. from Everest University and a B.S. in Psychology from Vanderbilt University.
Christopher Griffith | Founder & Vice President, Corporate Development & Strategy
Chris is a co-founder of Dermira and serves as our Vice President of Corporate Development and Strategy, bringing over 13 years of experience in corporate development, strategy and investment management. Prior to joining Dermira, he held corporate development, strategy and investment management roles at Gilead, Genentech, Inc. and Bay City Capital.
Chris received B.S. and M.S. degrees in biological sciences from Stanford University and an M.B.A. degree from Harvard Business School.
Andrew Guggenhime | Chief Operating Officer & Chief Financial Officer
Andrew joined Dermira in 2014 as our Chief Operating Officer and Chief Financial Officer and brings over 20 years of experience in finance and corporate development. Prior to joining Dermira, Andrew was the Chief Financial Officer for CardioDx, Inc., a molecular diagnostics life sciences company. He has also served as Chief Financial Officer for Calistoga Pharmaceuticals, Inc. until its acquisition in 2011 by Gilead, Facet Biotech Corporation until its acquisition in 2010 by Abbott Laboratories, PDL BioPharma, Inc. and Neoforma, Inc. Andrew began his career in financial services at Merrill Lynch & Co. and Wells Fargo & Company.
Andrew holds an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University and a B.A. in international politics and economics from Middlebury College.
Selwyn Ho, MB BS | Vice President, Market Access
Selwyn joined Dermira in 2016 as Vice President, Head of Market Access. Selwyn has nearly 20 years of broad functional biotech and pharmaceutical experience across primary care and specialist care markets. Prior to joining Dermira, Selwyn served as Vice President, Head of International Markets, Immunology at UCB and has held additional senior commercial and project lead roles within UCB, including Vice President, Global Mission Lead, CIMZIA® and Vice President, Head of Global Marketing, Immunology. He has also held leadership positions in regional roles, including General Management, Medical Affairs, Sales & Marketing and Market Access, at organizations including Allergan, Novartis and AstraZeneca.
Selwyn is a qualified physician, and earned his BSc in Pharmacology and his medical degree (MB BS) from Imperial College of Science, Technology & Medicine, University of London.
Hans Hofland, Ph.D. | Vice President, Research
Hans joined Dermira in 2013 as our Vice President, Research and brings over 20 years of experience in skin biology, topical medicines development and drug discovery. Prior to joining Dermira, Hans served as the Head of the Center for Skin Biology at Stiefel, a GSK company, where he was responsible for target identification and validation as well as early development of novel compounds in the dermatology portfolio for a wide variety of indications. He has held leadership positions at other companies, including Aventis, Inc., Optime Therapeutics, Inc. and Connetics.
Hans earned his Ph.D. in Pharmaceutical Sciences from the University of Leiden in the Netherlands, where he studied the interactions between topical drug delivery systems and human skin. He has co-authored over 20 book chapters and journal articles, and has 20 issued and pending patents in his name.
Delphine Imbert, Ph.D. | Senior Vice President, Pharmaceutical Sciences
Delphine joined Dermira in 2011 as our Vice President, Pharmaceutical Sciences with over 17 years of experience in the pharmaceutical industry. Prior to Dermira, Delphine served as Vice President of Pharmaceutical R&D at Anacor Pharmaceuticals, Inc. with previous experience at ALZA Corporation (a member of the Johnson & Johnson Family of Companies) and Cellegy Pharmaceuticals, Inc. Her scope of responsibilities have included leading efforts in transdermal and topical formulation development, product development, analytical development, clinical supplies, and related CMC filings from early- to late-stage development. She has also worked in multiple therapeutic areas, including onychomycosis, psoriasis, atopic dermatitis, acne, CNS and various infectious and neglected diseases.
Delphine has a M.S. in Chemistry and Chemical Engineering from the Ecole Nationale Supérieure de Chimie de Paris, a Ph.D. in Pharmaceutical Sciences from the University of Cincinnati, and was a NIH postdoctoral scholar at the University of California, San Francisco.
Lori Lyons-Williams | Chief Commercial Officer
Lori joined Dermira in 2016 as our Chief Commercial Officer and will be responsible for developing and implementing the commercial strategy for Dermira’s lead product candidates. She brings nearly 19 years of commercial experience to Dermira. Prior to joining Dermira, Lori spent 15 years in positions of increasing responsibility within the sales and marketing organization at Allergan, most recently as Vice President, Sales & Marketing for the Urology franchise. In this role, she helped to build what ultimately became one of Allergan’s fastest growing business units, and served as a member of the Allergan Commercial Leadership Team as well as the Operational Leadership Team. In previous roles within Allergan, she served as Product Director for Allergan’s medical dermatology brands and also held senior-level positions on the ACZONE® and BOTOX® marketing teams. Lori began her career at Johnson & Johnson as a pharmaceutical sales representative.
Lori holds an M.B.A from the Carlson School of Management of the University of Minnesota and a B.A. in Interdisciplinary Studies from Virginia Tech.
Luis Peña | Chief Development Officer
Luis is a co-founder of Dermira and serves as our Chief Development Officer. He brings over 25 years of product development and portfolio management experience. Prior to joining Dermira, Luis served as Vice President, Head of Global Prescription Development at Stiefel, and was Senior Vice President Portfolio Planning and Management at Stiefel Laboratories, prior to its acquisition by GlaxoSmithKline. He also held leadership roles in portfolio management and product development at Connetics, Nuvelo, Inc. and Theravance, Inc. as well as various positions in manufacturing, research and development at Genentech. Luis currently serves as an advisor to the SPARK program for the Stanford University School of Medicine.
Luis holds a B.S. in biochemistry from San Francisco State University.
Christine Ring, Ph.D. | Vice President, Legal
Christine joined Dermira in 2014 as our Vice President, Legal and brings over 20 years of legal experience. Prior to Dermira, she served as Senior Vice President, Technology Strategy and Licensing and Chief IP Counsel at Amyris, Inc., Director of Intellectual Property at Sunesis Pharmaceuticals, Inc. and Senior Patent Attorney at Kosan Biosciences Inc. Before becoming in-house counsel, she began her legal career in private practice, most recently as Senior Attorney at Pillsbury Madison & Sutro (now Pillsbury Winthrop Shaw & Pittman).
Christine has a J.D. from Hastings College of the Law, a Ph. D. in Pharmaceutical Chemistry from University of California, San Francisco, and an A.B. in Biophysics from University of California, Berkeley.
Mary Ellen Sillivos | Vice President, Human Resources
Mary Ellen joined Dermira in 2014 as our Vice President, Human Resources and brings over 20 years of HR experience in the biotech and pharmaceutical industry. Prior to joining Dermira, Mary Ellen held several leadership positions in the biopharmaceutical sector, including serving as Senior Director, Human Resources at Hyperion, Inc. and Executive Director, Human Resources at Affymax. She has broad experience in all aspects of human resource operations within early stage and start-up companies.
Mary Ellen attended the University of San Francisco and is a certified Senior Professional in Human Resources (SPHR).
Misbah Tahir | Vice President, Finance
Misbah joined Dermira in 2014 and has served as our Vice President of Finance since March 2016. He brings more than 18 years of finance and business planning experience, including over 12 years in the biotechnology industry. Prior to joining Dermira, Misbah held finance leadership positions of increasing responsibility at Onyx Pharmaceuticals, Human Genome Sciences, Inc. and Amgen. He began his career as a management consultant at Oliver Wyman, where he developed growth strategies for high-tech, energy and manufacturing clients.
Misbah is a certified public accountant (inactive) and earned a B.A. from the University of Pennsylvania and an M.B.A. from the University of Michigan.